# Autonomic dysfunction in patients with wild-type transthyretin amyloidosis

**Authors:** Vera E. A. Kleinveld, Julia Wanschitz, Anna Hotter, Corinne G. C. Horlings, Fabian Leys, Maria Ungericht, Gerhard Pölzl, Roberta Granata, Alessandra Fanciulli, Wolfgang N. Löscher

PMC · DOI: 10.1007/s00415-025-13604-0 · Journal of Neurology · 2026-02-27

## TL;DR

This study finds that wild-type transthyretin amyloidosis patients have impaired autonomic cardiovascular control, even though they rarely report autonomic symptoms.

## Contribution

First systematic investigation of autonomic dysfunction in wild-type transthyretin amyloidosis using standardized physiological tests.

## Key findings

- ATTRwt patients showed impaired blood pressure and heart rate regulation during orthostatic challenges compared to controls.
- 83% of ATTRwt patients had abnormal Valsalva Ratio, indicating autonomic dysfunction.
- Despite normal symptom scores, detailed testing revealed cardiovascular autonomic dysfunction in ATTRwt.

## Abstract

Autonomic dysfunction is well recognized in hereditary transthyretin amyloidosis (ATTRv), but it has not been systematically studied in wild-type transthyretin amyloidosis (ATTRwt). Because ATTRwt primarily presents with cardiomyopathy, autonomic symptoms may mimic heart failure and lead to inappropriate treatment. Here we aimed to investigate the presence and extent of autonomic dysfunction in ATTRwt.

In ATTRwt patients and controls, we performed an extensive autonomic examination, including standardized questionnaires, passive and active orthostatic challenges, Valsalva maneuver, deep breathing and sudomotor assessment.

20 ATTRwt patients and 20 controls were included. Composite Autonomic Symptom Score 31-scores were similar between the groups. Orthostatic challenges revealed impaired blood pressure (BP) and heart rate regulation in ATTRwt compared to controls (for passive orthostatic challenge: HR p = 0.001, systolic BP p = 0.010) and diastolic BP p = 0.006; for active orthostatic challenge: HR p = 0.001, systolic BP p = 0.002, diastolic BP p = 0.002). A lack of late phase 2 BP overshoot during Valsalva maneuver was observed in ATTRwt and Valsalva Ratio was pathological in 83% of ATTRwt versus 30% of controls (p = 0.020). The rate of pathological sweat tests did not differ between ATTRwt patients and controls.

Autonomic symptoms in ATTRwt were infrequently reported. However, detailed assessment revealed cardiovascular autonomic dysfunction, which contributes to the overall clinical phenotype of ATTRwt.

## Linked entities

- **Diseases:** cardiomyopathy (MONDO:0004994), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** TTR (transthyretin) [NCBI Gene 7276] {aka AMYLD1, ATTR, CTS, CTS1, HEL111, HsT2651}
- **Diseases:** hypertension (MESH:D006973), orthostasis (MESH:D004244), myocardial infarction (MESH:D009203), Cardiovascular autonomic dysfunction (MESH:D002318), atrial fibrillation (MESH:D001281), Classic orthostatic hypotension (MESH:D007024), peripheral (poly)neuropathy (MESH:D010523), hypertrophic cardiomyopathy (MESH:D002312), amyloid (MESH:C000718787), coronary artery disease (MESH:D003324), cardiac autonomic dysfunction (MESH:D006331), hypersensitive (MESH:D004342), ATTRwt amyloidosis (MESH:D000686), dry eyes and mouth (MESH:D014987), cardiac decompensation (MESH:D006333), autonomic neuropathy (MESH:D009422), Wild-type transthyretin amyloidosis (MESH:C567782), amyloid deposits (MESH:D058225), Parkinson's disease (MESH:D010300), orthostatic intolerance (MESH:D054971), orthostatic (MESH:D006261), vitamin B deficiencies (MESH:D014804), sympathetic adrenergic dysfunction (MESH:D006732), carotid artery stenosis (MESH:D016893), cardiovascular autonomic failure (MESH:D012791), presyncope (MESH:D013575), dyspnea (MESH:D004417), diabetes mellitus (MESH:D003920), heart valve stenosis (MESH:D006349), polyneuropathy (MESH:D011115), fatigue (MESH:D005221), aortic or mitral valve stenosis (MESH:D008946), QSART (MESH:D013736), ATTRwt cardiomyopathy (MESH:D009202), gastrointestinal dysmotility (MESH:D015154), arrhythmias (MESH:D001145), falls (MESH:C537863), Autonomic dysfunction (MESH:D001342), hypotension (MESH:D007022), bladder and sexual dysfunction (MESH:D001745)
- **Chemicals:** sodium (MESH:D012964), 3,3 phosphone-1,2-DPD (-), levothyroxine (MESH:D013974), tafamidis (MESH:C547076), nicotine (MESH:D009538), droxidopa (MESH:D015103), taurine (MESH:D013654), midodrine (MESH:D008879), etilefrine (MESH:D005039), 99mTc (MESH:D013667), fludrocortisone (MESH:D005438), acetylcholine (MESH:D000109)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948895/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948895/full.md

---
Source: https://tomesphere.com/paper/PMC12948895